ScopeSys builds analytical instruments based on Convex Lens-induced Confinement (CLiC) to observe and measure individual RNA and DNA molecules, capturing size, structure and dynamics at the particle level. The company pairs its physics-based CLiC technique with AI to accelerate scientific work, market analysis, product positioning and sales outreach. ScopeSys targets pharmaceutical and biotech teams that need particle-by-particle characterization to address heterogeneity, support formulation development, scale-up and quality control. The startup frames its go-to-market as a mix of service engagements to gain early validation and cash flow while progressing toward a repeatable instrument and consumables platform. Financially, ScopeSys reported a $1.1 million seed-based raise to fund prototyping and initial commercial use cases. The company positions itself as a commercial, revenue-oriented venture spun from research around the University of British Columbia environment.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2026